Market Closed -
Nyse
04:10:00 2024-05-31 pm EDT
|
5-day change
|
1st Jan Change
|
0.4
USD
|
-4.31%
|
|
+17.65%
|
+42.86%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
221.2
|
148.3
|
45.11
|
5.597
|
12.87
|
27.92
|
-
|
-
|
Enterprise Value (EV)
1 |
221.2
|
148.3
|
45.11
|
5.597
|
12.87
|
27.92
|
27.92
|
27.92
|
P/E ratio
|
-2.65
x
|
-4.91
x
|
-1.15
x
|
-0.2
x
|
-0.55
x
|
-0.67
x
|
-1.4
x
|
-1.38
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EV / Revenue
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EV / EBITDA
|
-
|
-5.28
x
|
-1.37
x
|
-0.22
x
|
-0.51
x
|
-0.84
x
|
-0.71
x
|
-0.61
x
|
EV / FCF
|
-13,597,200
x
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Yield
|
-0%
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Price to Book
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
22,835
|
23,241
|
28,196
|
29,977
|
45,974
|
69,806
|
-
|
-
|
Reference price
2 |
9.685
|
6.380
|
1.600
|
0.1867
|
0.2800
|
0.4000
|
0.4000
|
0.4000
|
Announcement Date
|
3/26/20
|
3/31/21
|
3/30/22
|
3/29/23
|
4/3/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBITDA
1 |
-
|
-28.08
|
-32.9
|
-25.7
|
-25.35
|
-33.4
|
-39.1
|
-45.9
|
EBIT
1 |
-22.21
|
-30.26
|
-35.46
|
-27.22
|
-25.35
|
-30.91
|
-36.74
|
-48.42
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Earnings before Tax (EBT)
1 |
-20.56
|
-30.09
|
-36.16
|
-28.25
|
-26.15
|
-41.41
|
-38.25
|
-49.69
|
Net income
1 |
-20.6
|
-30.1
|
-36.23
|
-28.32
|
-26.17
|
-41.42
|
-38.25
|
-49.69
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EPS
2 |
-3.660
|
-1.300
|
-1.390
|
-0.9500
|
-0.5100
|
-0.6000
|
-0.2867
|
-0.2900
|
Free Cash Flow
|
-16.26
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/26/20
|
3/31/21
|
3/30/22
|
3/29/23
|
4/3/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 S1
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 S1
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 S1
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBITDA
1 |
-14.72
|
-8.966
|
-7.154
|
-6.689
|
-13.84
|
-6.169
|
-5.18
|
-6.208
|
-5.856
|
-7.576
|
-5.272
|
-6.785
|
-7.7
|
-14.5
|
-8.7
|
-10.2
|
-
|
-
|
EBIT
1 |
-15.84
|
-9.785
|
-7.786
|
-7.324
|
-
|
-6.549
|
-5.56
|
-6.208
|
-6.073
|
-7.795
|
-5.272
|
-6.785
|
-6.759
|
-
|
-7.209
|
-7.669
|
-7.725
|
-8.884
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Earnings before Tax (EBT)
1 |
-15.73
|
-10.41
|
-8.16
|
-7.473
|
-15.63
|
-6.772
|
-5.847
|
-6.355
|
-6.403
|
-7.898
|
-5.49
|
-17.32
|
-7.498
|
-25.4
|
-8.182
|
-9.087
|
-7.971
|
-9.129
|
Net income
1 |
-15.74
|
-10.46
|
-8.169
|
-7.482
|
-15.65
|
-6.78
|
-5.886
|
-6.361
|
-6.411
|
-7.906
|
-5.491
|
-17.33
|
-7.501
|
-25.4
|
-8.187
|
-9.139
|
-7.971
|
-9.129
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EPS
2 |
-0.6500
|
-0.3600
|
-0.2700
|
-0.2500
|
-0.5300
|
-0.2300
|
-0.2000
|
-0.2000
|
-0.1200
|
-0.1300
|
-0.0800
|
-0.2800
|
-0.1050
|
-0.3800
|
-0.1150
|
-0.1200
|
-0.0400
|
-0.0400
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
8/16/21
|
3/30/22
|
5/11/22
|
8/10/22
|
8/10/22
|
11/9/22
|
3/29/23
|
5/15/23
|
8/9/23
|
11/14/23
|
4/3/24
|
5/20/24
|
-
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
|
-16.3
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
1 |
-
|
-
|
3.68
|
-
|
-
|
0.05
|
0.06
|
-
|
Capex / Sales
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/26/20
|
3/31/21
|
3/30/22
|
3/29/23
|
4/3/24
|
-
|
-
|
-
|
Average target price
2.833
USD Spread / Average Target +608.33% Consensus |
1st Jan change
|
Capi.
|
---|
| +42.86% | 22.09M | | +11.91% | 118B | | +11.60% | 106B | | -4.68% | 24.28B | | -0.82% | 21.96B | | -10.12% | 18.16B | | -42.12% | 16.37B | | -17.47% | 15.56B | | +2.77% | 13.63B | | +34.58% | 12.27B |
Bio Therapeutic Drugs
|